Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 4Completed 2Suspended 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Neoplasms 2Graft vs Host Disease 2Hematologic Neoplasms 1

Interventions

pembrolizumab 244Nivolumab 140Cisplatin 135Cyclophosphamide 134Paclitaxel 113Carboplatin 108Gemcitabine 98Radiotherapy 83Dexamethasone 83Docetaxel 77atezolizumab 68Ipilimumab 68Doxorubicin 62Fluorouracil 60Blood Specimen Collection 58Bevacizumab 58fludarabine 54Rituximab 54Etoposide 53Oxaliplatin 52Surveys and Questionnaires 49Lenalidomide 49Prednisone 47Standard of Care 45Magnetic Resonance Spectroscopy 45Cetuximab 44Capecitabine 44lenvatinib 43Radiosurgery 43durvalumab 42

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Abatacept × 1 year × Clear all
NCT01743131 2025-12-11

Abatacept as GVHD Prophylaxis Phase 2

Boston Children's Hospital

Phase 2 Completed
186 enrolled 14 charts 1 FDA

Graft vs Host Disease, Neoplasms

NCT03680092 2025-10-02

Comparing Cyclophosphamide and Abatacept With Standard of Care Treatment Following Stem Cell Transplantation

University of California, San Diego

Phase 2 Completed
43 enrolled 10 charts
Other hematologic neoplasm

Graft vs Host Disease, Neoplasms, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡